Dr. Besse on Combination of Necitumumab and Abemaciclib in NSCLC

Video

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of necitumumab (Portrazza) and abemaciclib (Verzenio) in patients with stage IV non–small cell lung cancer.

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of necitumumab (Portrazza) and abemaciclib (Verzenio) in patients with stage IV non—small cell lung cancer (NSCLC).

Findings from a phase Ib study showed that this combination failed to improve outcomes in this patient population. The 2-part, single-arm trial with an expansion cohort was designed to evaluate the safety and efficacy of the combination in comparison with historical data. Median progression-free survival (PFS) was 2.14 months (95% CI, 1.41-2.76) and median overall survival (OS) was 6.93 months (CI 95%, 4.96-12.85). The PFS rate at 3 months was 32.3% and 22.2% at 6 months. At 6 months, OS was 57.3%.

The activity of the combination was not as elevated as expected, says Besse, and the trial was considered negative. When compared with single-agent erlotinib (Tarceva) in non-driver NSCLC, the activity is quite similar, Besse explained. The combination should not be developed further unless a predictive biomarker for necitumumab or abemaciclib can be found. If a biomarker is defined, this combination could be revisited in a molecularly selected population, Besse concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD